Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Omaveloxolone

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Omaveloxolone?

Omaveloxolone is an investigational drug.

There have been 10 clinical trials for Omaveloxolone. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.

The most common disease conditions in clinical trials are Melanoma, Liver Diseases, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Reata Pharmaceuticals, Inc., AbbVie, and Covance.

There are two US patents protecting this investigational drug and forty-one international patents.

Recent Clinical Trials for Omaveloxolone
A Clinical Drug-Drug Interaction (DDI) Study With OmaveloxoloneCovancePhase 1
A Clinical Drug-Drug Interaction (DDI) Study With OmaveloxoloneReata Pharmaceuticals, Inc.Phase 1
A Human AME Study for OmaveloxoloneReata Pharmaceuticals, Inc.Phase 1

See all Omaveloxolone clinical trials

Clinical Trial Summary for Omaveloxolone

Top disease conditions for Omaveloxolone
Top clinical trial sponsors for Omaveloxolone

See all Omaveloxolone clinical trials

US Patents for Omaveloxolone

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Omaveloxolone   Start Trial 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof Reata Pharmaceuticals, Inc. (Irving, TX)   Start Trial
Omaveloxolone   Start Trial 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof REATA PHARMACEUTICALS, INC. (Irving, TX)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Omaveloxolone

Drugname Country Document Number Estimated Expiration Related US Patent
Omaveloxolone Argentina 092823 2032-04-27   Start Trial
Omaveloxolone Australia 2013251602 2032-04-27   Start Trial
Omaveloxolone Brazil 112014026640 2032-04-27   Start Trial
Omaveloxolone Canada 2869783 2032-04-27   Start Trial
Omaveloxolone Chile 2014002886 2032-04-27   Start Trial
Omaveloxolone China 104395332 2032-04-27   Start Trial
Omaveloxolone Colombia 7170182 2032-04-27   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.